News 2020-05-13
Porton Shanghai Formulation R&D Center Launched Construction
Shanghai, China, May 13, 2020 - Porton Pharmatech Co. ,Ltd. (Porton Pharmatech), a subsidiary of Porton Pharma Solutions Ltd. (Porton, Stock Code: 300363), today announced the commencement of construction of its Shanghai R&D Center, which would be Porton’s third formulation lab site that has been constructed since 2019. It has previously started design and construction of two other formulation labs based in Chongqing, China and New Jersey，USA.
Others
More
News 2026-08-05
Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
Porton Advanced Solutions Ltd. has officially been granted a Drug Manufacturing License (Class C) by the National Medical Products Administration (NMPA). This milestone qualifies Porton Advanced to undertake commercial contract manufacturing for Cell and Gene Therapy (CGT) products, extending its CDMO services from process development and clinical production through to the commercialization stage.
News 2026-07-08
Porton Advanced’s UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
Porton Advanced’s UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
